Business Wire

Luxembourg's Acceleration Programme Fit 4 Start Call for ICT and Space Tech Applications Open

Share

Fit 4 Start is Luxembourg’s acceleration programme for supporting start-ups. Start-ups benefitting from the programme, established in Luxembourg or another country, including outside the European Union, are selected twice a year. Launched by the Ministry of the Economy and managed by Luxinnovation, the Fit 4 Start programme has opened its next call for candidates for national and international start-ups.

The next edition of Fit 4 Start is aimed at young innovative companies active in the information and communication technologies sector (ICT) as well as the space technology sector. Registrations can be made online up until 20 January 2020 at 12.00 hours (midday Luxembourg time) via www.fit4start.com.

A pre-selection is carried out on the basis of the applications received. Candidates who are pre-selected will be notified on 3 February 2020. The pre-selected start-ups then meet for a ‘pitching’ session organised during the ‘Pitching and Graduation day’ which will take place on 26 March 2020 in Luxembourg City. 10 ICT and 5 space technology start-ups will be selected by an international jury to take part in the 10th edition.

Fit 4 Start offers to the 15 successful candidates a grant of €50,000, personalised and intensive coaching as well as free co-working space during four months at one of two incubator partners, Technoport and the Luxembourg City Incubator. An additional grant of €100,000 is awarded to start-ups which have successfully completed the programme and which have managed to raise at least €50,000 in private capital.

Contact information

Ministry of the Economy
Paul Zenners
Email: paul.zenners@eco.etat.lu
Tel.: (+352) 247-74126
Mobile: (+352) 621 409 141

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Test Company Announces Third Quarter Earnings24.1.2020 17:36:00 CETPress release

Test Company of San Francisco (NYSE:TEST) (TSX:TEST) (BSE:TEST) (LSE:TEST) issued their third quarter earnings statement today. Test Company reported diluted earnings per share of $0.11 in the third quarter of 2018, down by 1.1% from $1.01 in the third quarter of 2017, principally due to a $0.08 tax benefit recorded in 2017. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190807005678/en/ Test Photo with Caption - Violin - please visit www.businesswire.com for more details For XHTML support documents from Business Wire please view our tools site. Conference Call A conference call, hosted by John Doe, Chief Financial Officer, with members of the investment community and news media will be webcast at 9:00 a.m. Eastern Time on December 31, 2011. Access is available at www.businesswire.com. 2018 Full-Year Forecast Test Company increases its forecast for 2018 full-year reported diluted earnings per share to a range of $2.20 to $2.

HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated Lab of the Future24.1.2020 14:00:00 CETPress release

HighRes Biosolutions and Novo Nordisk A/S today announced that they will collaborate to design a state-of-the-art robotic platform for high-throughput biologics engineering and characterisation. The integration of a multi-system robotics platform with sophisticated software control architecture will enable a digital transformation and accelerated discovery for Novo Nordisk’s peptide and large molecule therapeutics research. “In order to maintain our leadership within biologics engineering we are investing in a fully automated and digital design platform. This investment is linked to our build-up in AI and advanced analytics and demonstrates Novo Nordisk’s commitment as a world leading biologics research company,” said Lars Fogh Iversen, senior vice president, Global Research Technologies, Novo Nordisk. The platform will comprise several highly automated and integrated cells for production, characterisation and functional analysis of thousands of biologic compounds every month. Its scop

Conquest Invests in 5 Greenfield Onshore Wind Parks Totalizing 43MW in the Flanders Region24.1.2020 12:37:00 CETPress release

Conquest, acting through the Conquest Sustainable Infrastructure fund, announced the transaction was closed after an exclusive agreement had been reached with ENGIE Electrabel. Conquest acquires 51% of a portfolio expected to provide 111 GWh per annum of renewable power representing the annual electricity consumption of about 32,000 Belgian homes from early 2021 onwards. The projects benefit from 15 to 20-year green certificates local remuneration schemes, and thus generate yearly secured revenues. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005221/en/ Credit: Electrabel While the energy and digital transitions continue to drive the infrastructure sector, Conquest keeps building its diversified sustainable real asset portfolio in Western European markets. The success lies in years of collaboration and long-lasting partnerships with fellow industry experts who can notably facilitate access to new growth opportunities

Fluence Expands EMEA Footprint with Horticulture Partners in Papenburg, Germany24.1.2020 11:00:00 CETPress release

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, announced today it is expanding its presence in the Emsland region of Germany through partnerships with growers and other horticulture specialists operating out of Papenburg. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005109/en/ Friedrich Schulz’s 5.5 hectare farm—which grows herbs year-round in addition to lettuce, peppers and chives—utilizing VYPR 2p fixtures. (Photo: Business Wire) Given Papenburg’s decades-long history of attracting horticulture experts, Fluence’s innovative lighting solutions for horticulture are a natural fit for the region’s tomato, cucumber, leafy greens and herb growers. Forging connections with Papenburg’s horticultural leaders Elektro Evers, an engineering firm specializing in greenhouse technology, is Fluence’s exclusive systems integrator

HCL Technologies Honors Global Goodwill Champions at the 2020 World Economic Forum in Davos24.1.2020 09:47:00 CETPress release

HCL Technologies (HCL), a leading global technology company, today presented its Wave Maker Awards 2020, commemorating global goodwill champions from around the world. The award ceremony, which was held at the HCL Pavilion in Davos, celebrated organizations and individuals passionately committed to such noble causes as diversity & inclusion, education & community upliftment, environment & sustainability, and technology for change. Special guest at the awards was Australian cricket legend Glenn McGrath, who is also founder of the McGrath Foundation, which provides support for Australian women diagnosed with breast cancer and their families. The award recipients were; Lois Auta, Founder and Executive Director of Cedar Seed Foundation, which supports persons with disabilities to participate in all aspects of life; Chido Govera, Founder and Director of The Future of Hope Foundation (TFoHF), which supports marginal and vulnerable members of society through entrepreneurial and self-developme

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria24.1.2020 06:00:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), as well as the ongoing Phase II (PVO-1A-202/204) extension studies. In both the Phase III and Phase II extension studies, palovarotene is dosed both chronically (daily) and episodically (during flare-ups). The decision to pause dosing patients in the trial is based on results of a futility analysis reviewed by the Independent Data Monitoring Committee (IDMC) as part of the prespecified interim analysis. The results of a futility analysis indicated that the Phase III FOP trial was unlikely to meet its primary efficacy endpoint (annualized change in new HO volume as compared with Natural History Studyi) upon completion. Despite the results of the prespecified interim analysis, signals of encouraging therapeutic activity w